Contrasting Opus Genetics (NASDAQ:IRD) and Kura Oncology (NASDAQ:KURA)

Opus Genetics (NASDAQ:IRD) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Volatility and Risk

Opus Genetics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Opus Genetics and Kura Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	24.07	-$49.59 million	($1.35)	-3.06
Kura Oncology	$67.48 million	10.38	-$278.67 million	($3.37)	-2.34

Opus Genetics has higher earnings, but lower revenue than Kura Oncology. Opus Genetics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Opus Genetics and Kura Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Kura Oncology	1	1	11	0	2.77

Opus Genetics currently has a consensus target price of $13.29, suggesting a potential upside of 221.30%. Kura Oncology has a consensus target price of $25.35, suggesting a potential upside of 222.15%. Given Kura Oncology’s higher probable upside, analysts plainly believe Kura Oncology is more favorable than Opus Genetics.

Profitability

This table compares Opus Genetics and Kura Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,726.70%	N/A	-146.19%
Kura Oncology	-369.26%	-265.89%	-44.40%

Summary

Opus Genetics beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

About Opus Genetics

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.